Microdosing and Off-label Use Cautions

She stresses lack of evidence for microdosing in people without obesity and need to evaluate risk–benefit ratios.

Play episode from 50:59

chevron_right

Transcript

chevron_right

Transcript

Episode notes

GLP-1 drugs like Ozempic and Mounjaro are now everywhere. But what do they actually do beyond weight loss? And what do you need to know before starting them?

In this episode, we’re joined by Dr Ania Jastreboff, a world-leading researcher at the forefront of GLP-1 treatments and writer of the New York Times bestselling book Enough: Your Health, Your Weight, and What It's Like To Be Free, co-authored with Oprah Winfrey.

Dr Jastreboff explains everything you need to know about Ozempic, Mounjaro, Wegovy and other GLP-1 medications for 2026. You’ll learn how GLP-1s may reduce the risk of heart disease, improve blood sugar control, and support conditions like sleep apnoea. We also explore why weight often returns after stopping, and what you need to know about Ozempic side effects and long-term use.

If these drugs can change how your brain controls hunger, what does that mean for willpower, weight gain, and how we treat obesity long term?

🌱 Try our science-backed and tasty wholefood supplement Daily30

Get our brand-new app and Gut Health Test designed by world-leading gut health and nutrition scientists to build healthy eating habits 👉 Join ZOE

Follow ZOE on Instagram.

Timecodes

00:00 Intro

04:25 What these drugs are really treating

06:42 The hunger problem nobody could name

10:57 The diabetes side effect that changed everything

12:15 Why Ozempic isn’t just “more GLP-1”

15:51 Why Mounjaro works differently to Ozempic

17:56 The part everyone gets wrong